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Abstract
Objective—To describe trends in Thailand’s antiretroviral treatment (ART) program 
performance assessed by HIV drug resistance early warning indicators (EWIs), as recommended 
by WHO, between 2009 and 2013.
Material and Method—Seven EWIs were monitored, viral load (VL) testing coverage, VL 
suppression, retention in ART, lost to follow-up (LTFU), antiretrovirals (ARVs) dispensing 
practices, on-time pill pick-up, and pharmacy stock-outs. Data from ART adult patients in 
National Health Security Office Scheme were analyzed except for pharmacy stock-outs, which 
were reported from hospitals. Aggregated averages were calculated for each EWI. Chi-square for 
trend was applied to measure significant changes.
Results—By September 2013, 174,284 adults were receiving ART at 929 hospitals. Over time, 
improvement in VL testing coverage (53.8% in 2009 to 79.8% in 2013) was observed. VL 
suppression and on-time pill pick up rates were well above 90%. Rates of retention in ART 
declined from 84.0 to 82.9%, whereas LTFU rates increased from 8.3 to 9.2% (p<0.001). 
Prescriptions with inappropriate ARVs decreased from 0.32 to 0.10% (p<0.001). Of reporting 
hospitals, 96.1%, 96.3%, and 96.2% observed no ARVs stock-out between 2011 and 2013.
Conclusion—EWI is a useful tool to monitor ART program performance and to identify area 
where improvement is needed.
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In 2002, Thailand initiated a program to scale up antiretroviral treatment (ART) for all 
people living with HIV(1). In 2006, Thailand included ART benefits in the Universal Health 
Coverage (UC) scheme for Thai nationals, thus further accelerating ART access(2). As of 
September 2013, 246,049 people living with HIV (PLHIV) were receiving ART, 
representing 80.3% of those qualifying for ART initiation, based on the eligibility threshold 
of CD4 350 cells/µl or less. Of those on ART, 92.3% were receiving ART free of charge 
through three public health welfare benefit schemes: the National Health Security Office 
Scheme (NHSO, 71.4%), the Social Security Scheme (SSS, 17.8%), and the Civil Servant 
Medical Benefit Scheme (CSMBS, 3.1%)(3).
To be reimbursed for antiretroviral medicines (ARVs) and laboratory tests, ART clinics in 
Thailand must comply with national HIV/AIDS treatment guidelines, including compliance 
with the recommended regimen for first-line treatment (2NRTIs + 1NNRTI) and regular 
viral load (VL) testing to monitor ARV efficacy. National guidelines recommend VL testing 
of all patients six months after initiating ART and annually thereafter(4). If VL test results 
are greater than 50 copies/ml, guidelines stipulate intensive adherence counseling with a 
follow-up VL test after three months. Patients with confirmed treatment failure identified by 
the second VL test, defined as VL greater than 1,000 copies/ml, or with verified compliant 
ART adherence are eligible for HIV drug resistance (HIVDR) genotyping. Authorization to 
switch to a second-line or alternative regimen, indicated by treatment failure as described in 
national guidelines, requires evidence of HIVDR mutation, and the agreement of certified 
HIV/AIDS specialists.
Despite the mandatory implementation of standard guidelines, there have been concerns 
about the potential emergence of HIVDR, which could hamper the efficacy of current ART 
regimens. Improper use of ARVs can lead to viral mutations associated with HIVDR. 
Appropriate patient education, adherence support, and good program management may help 
limit improper ARV use. A shortage of staff to provide counseling and treatment, in the 
context of accelerated program scale-up, may result in insufficient counseling and adherence 
support. Likewise, shortages of properly trained health care workers may impede appropriate 
clinical and laboratory monitoring. Inefficient drug procurement and supply chain systems 
may lead to stock-outs of medicines, potentially interrupting treatment. For patients, there 
are several factors that can enhance or hinder treatment adherence and continuity. Moreover, 
the recent change in the national strategy to initiate ART regardless of CD4 cell count in 
order to improve treatment outcomes and to promote a treatment-as-prevention strategy(5) 
has led to concerns about the risk of HIVDR emergence and transmission resulting from 
suboptimal adherence among asymptomatic and/or less-motivated patients.
To ensure sustainable public funding and resources to support the national ART program, 
Thailand’s national strategy has focused on optimizing the long-term efficacy and durability 
of current first-line regimens by minimizing patient- and program-level factors associated 
with the emergence of HIVDR. HIVDR surveillance and monitoring of early warning 
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indicators (EWIs), recommended by the World Health Organization (WHO), is a 
fundamental element of the strategy to alert policy makers, health care providers and 
program managers of HIVDR situation and potential risks of HIVDR emergence. EWIs are 
patient, clinic and program factors known to be associated with increased risk in HIVDR 
emergence. The timely identification of these factors can prompt appropriate corrective 
actions, thus maximizing HIVDR containment and prevention efforts. Guidance on EWI 
definition and corresponding targets published by WHO in 2010(6) and revised in 2011(7) 
recommend a simple package of five EWIs that was adapted for implementation in Thailand.
In addition to the monitoring of EWIs, surveys to measure level of HIVDR were also 
conducted among pretreatment antiretroviral-naïve HIV infected patients (PDR). Between 
2006 and 2013, Bureau of AIDS, TB and STIs (BATS), Department of Disease Control 
(DDC) had conducted four PDR surveys in sampled clinics. The results demonstrated an 
increasing trend of HIVDR prevalence among pre-treatment cases from 1.9% in 2006 to 
2.8%, 3.8%, and 5.6% in 2007, 2008, and 2013, respectively. Furthermore, follow-up study 
to monitor acquired HIVDR (ADR) among HIV infected cases at 24 months after ART 
initiation was also conducted. It was observed that HIVDR prevalence rose from 1.9 to 2.8% 
among the cohort starting ART in 2006 and from 2.8 to 3.5% among the cohort starting ART 
in 2007(8,9). Other studies’ results found 2 to 17.6% of HIVDR prevalence among 
pretreatment antiretroviral-naïve patients during 2002 to 2011. The prevalence rates 
identified from each study varied depending on study sites and methodology(10–14).
In 2007, NHSO developed the National AIDS Program (NAP) database, an electronic, web-
based patient monitoring system that was subsequently implemented nationwide. The 
primary purpose of the NAP database is to send real-time health care spending data to the 
NHSO so health care providers and hospitals can be reimbursed for the services they provide 
to patients. Data about medical services, including HIV counseling and testing, appointment 
keeping, ART prescription, and laboratory results are submitted online by HIV coordinators 
and laboratory technicians in hospitals. Patient records are web-based and linked in real-time 
with the national death registry using a national personal identification number to identify 
living persons. NAP data is processed centrally for the purpose of authorizing 
reimbursement of hospital expenditures associated with service delivery. NAP data is also 
used to monitor ART services and their performance. NHSO uses an anonymous unique 
identifier, the NAP-ID, to ensure patient privacy. The NAP-ID is generated at patient 
registration and used for data management. Access to patient information is password 
protected and limited to care providers providing services to the patient.
Since 2010, Thailand’s BATS, the NHSO, the Thailand Ministry of Public Health (MOPH)-
U.S. Centers for Disease Control and Prevention (U.S. CDC) Collaboration (TUC), and their 
partners have implemented a project to prevent HIVDR using EWIs. NAP data and 
pharmacy stock-out annual reports were used to measure HIVDR EWIs. This article 
presents Thailand’s experiences using EWIs to describe trends in ART program performance 
between 2009 and 2013.
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Data recorded in the NAP database about HIV-infected adults aged 15 years or older that 
health care costs were covered by Thailand’s NHSO scheme and were enrolled between 
fiscal years 2009 and 2013, were used for analysis. The cut-off date for data used in this 
article was September 30, 2014.
Definition of EWIs for national program monitoring
Since 2010, EWIs for Thailand and their operational definition were slightly modified from 
WHO guidelines to suit the country context. Consensus on modifications was established 
during several consultative discussions among national academics, Thailand ART program 
managers at various health system levels, and experts from the U.S. CDC and WHO. The list 
of EWIs was shown in Table 1.
Measurement tools
NAP database—NAP data about medical and laboratory services provided to ART adult 
patients were used to analyze all EWIs except for the ARVs stock-outs. A query was 
developed and executed quarterly via structured query language (SQL) server to generate 
standard EWI reports for hospital and national levels in aggregated format without linkage to 
NAP-ID or any personal identifier. Percentage of ART clinics that met the desirable, fair, 
and poor target criteria of each indicator were monitored for each year. No informed consent 
was required as data used in this study are secondary anonymous data from the NAP 
database.
Hospital pharmacy stock-out report—According to the national ART program 
management, pharmacists at the ART clinics have been requested to report online drug 
stock-out status, either at one point-in-time or over a period of days, to BATS on an annual 
basis since 2011. The percentage of months in the reporting year in which there were no 
stock-out days of the ARV drug was calculated for each ART site. Percentage of ART clinics 
that meet the desirable target was monitored at national level annually and used for these 
EWI reports.
Data analysis
Variables included in the analysis were dates of key events (birth, clinic visit, VL tests, and 
death), ARV regimens prescribed, and VL tests performed and VL test results. Patient and 
service data were analyzed and EWI results were presented in aggregated average format 
with 95% confidence interval (CI). Tests of EWI performance trends over time were 
performed using Chi-square for trend by Epi Info™ 7 software(15).
Clinic’s performance was categorized according to its ability to meet the desired target for 
each EWI (desirable, fair, or poor for VL testing coverage, VL suppression, retention, LTFU, 
and on-time pill pick-up; and desirable or poor for ARVs dispensing practices and ARVs 
stock-outs). Where data was not available for a clinic or if a clinic did not report data on 
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ARVs stock-outs, it was excluded from analysis. Proportion of clinics classified by 
performance was presented.
Results
As of September 2013, all of the 929 ART clinics providing treatment for adult patients in 
all 77 provinces of the country have monitored EWIs. Between 2009 and 2013, the number 
of patients aged 15 years or older, receiving ART through the NHSO scheme varied from 
110,924 to 174,284 cases by year. Number of adult ART patients achieving 12 months of 
treatment after ART initiation ranged from 21,428 to 18,113 (Table 2).
Results of selected EWIs (VL coverage, VL suppression, retention in care, lost to follow-up, 
ARVs dispensing practices and ARVs on-time pill pick-up, ARVs stock-outs) between 2009 
and 2013 are presented in Table 2 and the proportion of clinics that met desirable targets of 
all indicators in the same period are shown in Table 3.
The analysis of the VL indicators showed that coverage of VL testing at 12 months after 
ART initiation had significantly improved over time, increasing from 53.8% in 2009 to 
79.8% in 2013 (p<0.001). VL suppression rate, however, has remained stable at 93 to 95% 
during the same years. The proportion of patients retained in care 12 months after ART 
initiation slightly declined from 84.0 to 82.9% (p = 0.086), and the proportion of patients 
lost to follow-up increased significantly from 8.3 to 9.2% (p<0.001). We observed a 
significant decline in the proportion of patients prescribed a mono or dual ART regimen, 
from 0.32% in 2009 to 0.10% in 2013 (p<0.001), while on-time pill pick-up leveled off at 
91% over the five-year period.
Table 3 showed that the proportion of clinics meeting the desired target for VL coverage 
(greater than 90%). It increased from 12.6% in 2009 to 38.2% in 2013, although in 2013, 
42.2% of clinics still reported a less-desirable uptake of VL testing (less than 80%).
With respect to VL suppression at 12 months after ART initiation, we initially observed an 
increased proportion of clinics meeting the desirable target of 90% or greater suppression 
rate (from 78.0 to 79.4% of the clinics in 2009 and 2011 respectively) before a decrease to 
74.7% in 2013.
The proportion of clinics meeting the target of greater than 85% of the patients retained in 
care at 12 months was quite stable over time (from 55.4% in 2009 to 53.2% in 2013) while 
the clinics reporting more than 10% of patients lost to follow at 12 months increased from 
27.9% in 2009 to 31.4% in 2013.
Although clinic’s ARV dispensing practices improved over the five years, and in 2013 the 
vast majority (87.7%) achieved the desirable target of 0% prescriptions of mono- and dual-
therapy, 114 clinics (12.3%) were still prescribing mono or dual ART regimens to some 
patients. In the same year, 64.5% of clinics met the desired target of greater than 90% of the 
patients picking up their ARVs on-time, while 13.4% of clinics had poor performance on 
this indicator (less than 80% of patients on-time for ARVs pick-up).
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BATS received the hospital pharmacy stock-out reports from 615, 455 and 340 ART clinics 
in 2011, 2012 and 2013, respectively. Of these, 96.1% (95% CI 94.2 to 97.3), 96.3% (95% 
CI 94.1 to 97.8), and 96.2% (95% CI 93.6 to 97.9) of clinics reported no ARVs stock-out 
days during 2011, 2012, and 2013, respectively.
Discussion
HIV drug resistance EWIs (VL coverage, VL suppression, retention in care, lost to follow-
up, ARVs dispensing practices, and ARVs on-time pill pick-up) were monitored over a five-
year period (2009 to 2013) in 921 to 929 clinics dispensing ART in Thailand. By using the 
routine national patient monitoring system, the analyzed data covered 70.8% of all cases, 
providing a very comprehensive picture of overall quality of care in the ART program.
Overall, significant improvements in VL testing coverage and appropriate dispensing 
practices were observed over the five-year period, although a sizeable proportion of clinics 
still lag behind. For other indicators such as VL suppression and on-time pill pick-up, 
average performance was sustained above the desired level. However, the average 
performance of clinics regarding retaining patient in care, minimizing lost to follow-up, 
preventing pharmacy stock-outs, and maximizing on-time pill pick-up did not achieve 
desired national targets.
Interpretation of VL coverage and suppression in the EWI setting must be done cautiously. 
The VL suppression indicator represents results among patients with VL test results, hence it 
should not be interpreted as including all patients on ART.
Thailand created two separate VL indicators, one for VL coverage and another for VL 
suppression, which differ from WHO recommendations(7). The reason was to examine the 
possible role of low coverage of VL testing resulting in poor VL suppression. These 
additional data should allow program management to improve the quality of service by 
identifying areas and hospitals where VL testing coverage is insufficient, thus leading to 
further improvement.
As Thailand is moving towards its goal of Ending AIDS, it recently embraced the ambitious 
target of 90-90-90(16) which aims to let 90% of all PLHIV to know their HIV status, 90% of 
diagnosed HIV infection to receive sustained ART, and 90% of all people receiving ART to 
have viral suppression. It is therefore essential to advocate for more uptake of VL testing 
and revision of the targets in both indicators (VL coverage and VL suppression) is required 
in order to reflect the yield of ART to reach VL suppression of 90% among all ART cases. 
In the Thai context, a VL test can be offered to every individual patient on ART with certain 
frequency as it is included in ART benefit package provided by all health security programs. 
Costs for VL test performed on all patients on ART conducted twice a year during the first 
12 months or up until VL are below suppression level are fully subsidized. VL tests can then 
be repeated once every year after the first year if VL is found to be suppressed.
The proportion of PLHIV retained in care declined from 84.0% in 2009 to 82.9% in 2013. 
This is slightly higher than retention rates reported elsewhere, i.e., the rate observed in 
cohorts of adult cases starting ART in 2007 in Vietnam was 81.2% in 2008(17). The average 
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rates of lost to follow-up increased from 8.3 to 9.2% (p<0.001). Comparing this rate with 
other countries might be difficult due to variation in the definition. Since the NAP database 
is linked to the national death registration system and ART cases who died will not be 
counted in the analysis of this indicator, the data shown here represented those who do not 
come back to receive continuous ART while data from other countries may include deaths in 
their loss to follow-up setting. It was found that lost to follow-up in Thailand may be higher 
than in Vietnam (5.6%, in 2008)(17), China (1.4 to 5.6%, in 2006 to 2007)(18), and lower 
than what were observed in African countries such as in Cameroon (4 to 77%, in 2010)(19). 
However, the results were greater than the loss to follow-up target of <5%. This observation 
raised a concern about ART program management and activities to foster patients to return 
for continuity of ART. In 2013, there were 49.6% of ART sites that did not meet the desired 
target for this indicator, suggested the need to improve follow-up activities.
Data from EWIs were used to identify ART sites where there were needs for further quality 
service improvement. This was done by regular review of the EWIs’ results from each 
province, which was displayed on a public website, by the regional technical AIDS 
committee. Provinces where ART service performances in relation to EWIs poorer than the 
others were approached by the experts in the regional technical committee and interventions 
to improve service performances were implemented. Activities such as coaching to improve 
service quality were planned and launched, and EWIs analysis was repeated regularly in 
order to demonstrate change in their performance over time. One illustrative example was on 
the improvement of VL testing coverage which was the results of activities carried out by 
the regional technical committees. After reviewing the EWIs, the committee members 
visited the selected clinics and discussed with physicians and ART clinic management ways 
to improve uptake of VL tests, and based on these proposed activities, the VL test coverage 
increased.
A strong argument for use of the Thailand’s EWIs system is that it is a service-based patient 
monitoring system for which hospital providers at all ART sites routinely record service 
delivery parameters and patient outcomes via real-time electronic data entry. This practice 
provides an opportunity to measure almost all of the EWI indicators including VL coverage, 
VL suppression, retention in care, lost to follow-up, dispensing practices, and on time pill 
pick-up. The countrywide, electronically, and continuous management enables program 
managers at clinic, provincial and regional levels to compare and identify ART clinics where 
performance is substandard and monitor their performance over-time. At present, software to 
analyze NAP data for each EWI has been developed and the results are published on the 
NHSO website(20).
The present analysis had some limitations. Firstly, the population used for the analysis was 
restricted to adult patients receiving ART from the NHSO scheme. However, starting in 
2014, there will be an opportunity to analyze data of patients who are receiving ART by the 
CSMBS and SSS. This was a result from a recent development on expanding NAP to 
monitor service delivery cascade and outcomes of all patients. Hospitals are required to enter 
ART data from all schemes of public health care insurances into the revised NAP database 
that was renamed as NAP+. Secondly, the number of ART sites in each year was not 
consistent and some of the variability in the indicators by time might reflect sites moving in 
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and out of the calculations. In the present analysis, only ART sites with patients met the 
definitions of EWIs were recruited. The sites with small number of patients, i.e., small 
community hospitals, are more likely to be inconsistently recruited across time. Additional 
data analysis by aggregating data from all ART sites in each province to minimize the 
variability caused by moving in and out of small ART sites is being considered in order to 
minimize the variability and promote the data use as for provincial program improvement. 
Finally, there was the relatively small number of hospitals submitting the pharmacy stock-
out reports. The annual reporting rates declined over time. The reason for this 
underreporting may be the complicated reporting process in which the pharmacy stock-out 
report was integrated with the other requirements on hospital service delivery profiles or 
unclear instructions. It was therefore decided to revise the system focusing the pharmacy 
stock-out report with clear instruction in the next round of the annual report.
EWIs play an important role in HIVDR surveillance and prevention program in Thailand. As 
recommended by WHO(21,22), other incorporated activities include a minimum package of 
pretreatment(23) and acquired HIVDR surveillance, and establishment of expert committees 
to manage issues related to HIVDR. For EWI management, there is a need for further 
improvement both in terms of quality of data, and utilization of the results by ART clinic 
staff and all stakeholders at various levels to ensure that patients will receive quality 
services.
Interpretation of the EWIs’ data together with the results of the PDR and ADR surveys in 
Thailand which revealed increasing trends of HIVDR both in the pretreatment cases and in 
the follow-up of treated cases, pointed out the urgency of the ART program to further 
strengthen ART sites to deliver quality services to ensure VL suppression and cases’ 
adherence to appropriated ARV regimen. These actions will benefit in the minimizing of 
HIVDR occurrence and stewardship of the current ART.
At present, a medium-term national action plan, starting from 2015 onward, has been 
developed in accordance with the WHO Global HIV Drug Resistance Network 
recommendation and from this plan the activities on HIVDR surveillance and prevention 
will be carried out. The implementation of HIVDR surveillance and prevention activities is 
critical to preserve the long-term effectiveness of available and affordable ARVs both in the 
context of treatment for all people with HIV and for HIV prevention.
Conclusion
EWI is a useful tool to monitor ART program performance and to identify area where 
improvement is needed.
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What is already known on this topic?
EWIs are recommended by WHO for monitoring the potential risks of HIV drug 
resistance emergence in countries implementing ART program. EWIs monitor patient, 
clinic and program factors known to be associated with increased risk in HIVDR 
emergence. Experience of using EWIs and their results have been published by some 
countries except Thailand.
What this study adds?
This article presented EWI results of Thailand by using national database collected from 
all ART clinics under NHSO scheme from 2009 to 2013 for the HIV drug resistance 
monitoring. It assessed trends of Thailand ART program performance.
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Table 1
List of early warning indicators (EWIs)
EWIs Description Target
VL coverage Percentage of patients receiving ART at the site who had received VL testing during the 
first 12 months of ART
- Numerator: number of patients who had at least one VL screening during 3 to 12 months of 
ART
- Denominator: number of patients retained on ART at 12 months after initiation at the site 
who by national policy should have had a VL performed during 3 to 12 months of ART
Desirable: ≥90%
Fair: 80 to 89%
Poor: <80%
VL suppression Percentage of patients receiving ART at the site whose VL was <1,000 copies/ml during 
the first 12 months
- Numerator: number of patients whose VL (the latest VL tested during 3 to 12 months of 
ART) was <1,000 copies/ml
- Denominator: number of patients retained on ART at 12 months after initiation who had at 
least one time VL screening during 3 to 12 months of ART
Desirable: ≥90%
Fair: 80 to 89%
Poor: <80%
Retention in care Percentage of patients known to be alive and on treatment 12 months after initiation of 
ART
- Numerator: number of patients who are still alive and on ART 12 months after initiation
- Denominator: number of patients who were expected to achieve 12-month outcomes within 
the reporting year, including those recorded as dead, stopped therapy, or lost to follow-up 
during 12 months of ART
Desirable: >85%
Fair: 75 to 85%
Poor: <75%
Lost to follow-up Percentage of patients lost to follow-up at 12 months of ART
- Numerator: number of patients who did not return to the clinic >90 days after the last 
missed appointment or drug pick-up date during 12 months of ART
- Denominator: number of patients who were expected to achieve 12-month outcomes within 
the reporting year, excluding those who were recorded as dead or transferred out during 12 
months of ART
Desirable: <5%
Fair: 5 to 10%
Poor: >10%
Dispensing practices Percentage of patients prescribed mono or dual ARV therapy
- Numerator: number of patients receiving ART at the end of the reporting year and 
prescribed a regimen consisting of one or two ARVs at their last clinic visit
- Denominator: number of patients receiving ART at the end of the reporting year
Desirable: 0%
Poor: >0%
On-time pill pick-up Percentage of patients who picked up ART no more than two days late at the first pick-up 
after baseline pick-up
- Numerator: number of patients prescribed ART during a baseline month who returned for 
their next pill on time (within 2 days of their baseline month prescription running out if 
taken according to schedule)
- Denominator: number of patients prescribed ART during the baseline month of the 
reporting year
Desirable: >90%
Fair: 80 to 90%
Poor: <80%
Pharmacy stock-outs Percentage of months in a reporting year in which there were no ARV drug stock-out
- Numerator: number of months in the reporting year in which there were no stock-out day 
of any ARV drug routinely used at the site
- Denominator: 12 months
Desirable: 100%
Poor: <100%
VL = viral load; ART = antiretroviral treatment; ARV = antiretroviral
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